Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?

Susanna V Ulahannan; Austin G Duffy

doi:10.2217/hep-2016-0008

Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?

Hepat Oncol. 2016 Aug;3(3):183-185. doi: 10.2217/hep-2016-0008. Epub 2016 Aug 19.

Authors

Susanna V Ulahannan^{1

1}, Austin G Duffy^{2

2}

Affiliations

¹ Cancer & Blood Care, 609 Virginia Ave, Ponca City, OK 74601, USA.
² Gastrointestinal Malignancies Section, Thoracic & GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20850, USA.

No abstract available

Keywords: CTLA-4 inhibitor; PD-1 inhibitor; RFA; TACE; check point inhibitors; hepatocellular carcinoma; immune tharapy; radiofrequency ablation; transcatheter arterial chemoembolization.

Publication types

Editorial